Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.
Phase I: The purpose of this study is to determine which of the subcutaneous doses of
decitabine administered twice daily for 5 days maximizes genomic demethylation in patients
Phase II: To evaluate hematological responses at the dose selected in the Phase I portion of
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase I: To determine which of the subcutaneous (SQ) doses of decitabine administered twice daily for 5 days maximizes genomic demethylation in patients with MDS.
United States: Food and Drug Administration
|Albert Einstein College of Medicine||Bronx, New York 10461|
|University of Arizona Cancer Center||Tucson, Arizona 85724|
|H Lee Moffitt Cancer Center & Research Institute||Tampa, Florida 33612|